Olema Oncology reports Q2 EPS (51c), consensus (44c)

Cash, cash equivalents, and marketable securities of $361.9M as of June 30. “Having achieved regulatory alignment on the selected dose for our pivotal palazestrant program during the second quarter, we are focused on accelerating enrollment in OPERA-01, which is on track for top-line data in the second half of 2026, and initiating the OPERA-02 combination trial in the frontline setting,” said Sean Bohen, president and CEO of Olema Oncology (OLMA). “Palazestrant’s demonstrated activity and combinability with multiple compounds offers the potential for it to become a best-in-class, backbone endocrine therapy for metastatic breast cancer. Our Phase 1 study of OP-3136, our potent and selective KAT6 inhibitor, is also generating strong investigator interest and patient enrollment, reinforcing our leadership in developing novel therapies for breast cancer and beyond.”